$1.79 EPS Expected for Johnson & Johnson (JNJ)

September 17, 2017 - By Kurt Siggers

 $1.79 EPS Expected for Johnson & Johnson (JNJ)
Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.12, from 0.82 in 2016Q3. It increased, as 63 investors sold Johnson & Johnson shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported.
Pioneer State Bank N A Or invested in 2.31% or 34,058 shares. Wedgewood Invsts Pa stated it has 1.28% of its portfolio in Johnson & Johnson (NYSE:JNJ). Torray Ltd Limited Liability Company reported 1.39% of its portfolio in Johnson & Johnson (NYSE:JNJ). Brick & Kyle holds 2.06% in Johnson & Johnson (NYSE:JNJ) or 22,259 shares. Old Bankshares In reported 178,264 shares or 1.18% of all its holdings. 6,611 are owned by Sfmg Llc. California-based Ssi Investment has invested 0.08% in Johnson & Johnson (NYSE:JNJ). Mitchell Mcleod Pugh & Williams accumulated 17,493 shares. Piedmont Inv Advsrs Lc holds 0% or 703,402 shares in its portfolio. Joel Isaacson & Commerce Ltd Liability Corp holds 1.02% or 44,012 shares in its portfolio. Checchi Advisers Ltd Liability Co has 31,523 shares. Sageworth Tru holds 5,001 shares. Boltwood Capital invested in 1.64% or 18,577 shares. Sheets Smith Wealth Mngmt reported 14,462 shares or 0.47% of all its holdings. Ameriprise Fincl accumulated 1.1% or 17.43M shares.

Analysts expect Johnson & Johnson (NYSE:JNJ) to report $1.79 EPS on October, 17 before the open.They anticipate $0.11 EPS change or 6.55 % from last quarter’s $1.68 EPS. JNJ’s profit would be $4.80B giving it 18.78 P/E if the $1.79 EPS is correct. After having $1.83 EPS previously, Johnson & Johnson’s analysts see -2.19 % EPS growth. The stock increased 0.13% or $0.18 on September 15, reaching $134.45. About 15.52M shares traded or 199.04% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since September 17, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 22 analysts covering Johnson & Johnson (NYSE:JNJ), 10 have Buy rating, 4 Sell and 8 Hold. Therefore 45% are positive. Johnson & Johnson had 64 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, October 7 by RBC Capital Markets. The firm earned “Outperform” rating on Wednesday, July 20 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Sunday, August 27. The stock of Johnson & Johnson (NYSE:JNJ) earned “Overweight” rating by Barclays Capital on Wednesday, April 20. Barclays Capital downgraded the stock to “Equal-Weight” rating in Tuesday, November 29 report. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, April 20. The rating was maintained by UBS with “Buy” on Thursday, August 31. The stock has “Neutral” rating by Goldman Sachs on Monday, March 14. BMO Capital Markets maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, August 31. BMO Capital Markets has “Buy” rating and $145.0 target. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by Cowen & Co on Tuesday, August 25.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has market cap of $360.86 billion. It operates through three divisions: Consumer, Pharmaceutical and Medical Devices. It has a 22.73 P/E ratio. The Company’s primary focus is products related to human health and well-being.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Pfizer Punches Back at Johnson & Johnson in Prostate Cancer” on September 15, 2017, also Washingtonpost.com with their article: “Johnson & Johnson says its drug shouldn’t be used in executions” published on August 22, 2017, Seekingalpha.com published: “Johnson & Johnson’s (JNJ) Management Presents at Morgan Stanley Healthcare …” on September 14, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Realmoney.Thestreet.com and their article: “Johnson & Johnson Is Getting Ready for Another Upside Breakout” published on September 15, 2017 as well as Seekingalpha.com‘s news article titled: “Johnson & Johnson – This Is A Dividend Machine” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: